Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02454972 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
A Phase 2 study of Advanced Solid Tumors, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 2
- Development phase
- 345
- Enrollment target
- 20
- Study locations
NCT02454972 is a Phase 2 study of Advanced Solid Tumors that has completed, run by PharmaMar. The registered enrollment target is 345 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (76% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT02454972, a Phase 2 study of Advanced Solid Tumors, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 345 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, open-label, exploratory, phase II clinical trial to evaluate the efficacy and safety of PM01183 in previously treated patients with advanced solid tumors
Conditions Studied
Interventions
- DRUG lurbinectedin (PM01183)
Study Locations (20)
Other
- Institut Jules Bordet - Brussels
- Hôpital Cochin - Paris
- Institut Claudius Regaud - Toulouse
- Institut Gustave Roussy - Villejuif
- Charité Universitätsmedizin Berlin - Campus Benjamin Franklin - Comprehensive Cancer Center - Berlin
- Charité - Universitätsmedizin Berlin - Berlin
- Istituto Ortopedico Rizzoli - Bologna
- lstituto Europeo di Oncologia - Milan
- ASST Monza - Ospedale San Gerardo di Monza Struttura Complessa di Oncologia Medica - Monza
- AUSL Romagna - Ospedale Santa Maria delle Croci - Ravenna
Massachusetts
- Massachussets General Hospital - Boston
- Beth Israel Deaconess Medical Centre - Boston
- Dana Farber Cancer Institute - Boston
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- Institute for Drug Development, Cancer Therapy & Research Center at University of Texas Health Science Center - San Antonio
California
- Sarcoma Oncology Research Center, LLC - Santa Monica
Colorado
- University of Colorado Cancer Center - Aurora
Milan
- Istituto Clinico Humanitas - Rozzano
A Coruña
- Complexo Hospitalario Universitario de Santiago - Santiago de Compostela
Guipúzcoa
- Hopsital Universitario Donostia - Donostia Unibertsitate Ospitalea - San Sebastián
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2015-08-25 |
| Est. Completion | 2020-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02454972
The ClinicalTrials.gov registry entry for NCT02454972 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (76% higher). The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which lurbinectedin (PM01183) is the first listed.
NCT02454972 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT02454972 about?
NCT02454972 is a clinical study titled "Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors". Multicenter, open-label, exploratory, phase II clinical trial to evaluate the efficacy and safety of PM01183 in previously treated patients with advanced solid tumors
What is the current status of trial NCT02454972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 345 participants. The study started on 2015-08-25. Estimated completion is 2020-09-18.
What conditions does trial NCT02454972 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT02454972?
The interventions under investigation include: lurbinectedin (PM01183) (DRUG).
Who is sponsoring clinical trial NCT02454972?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02454972 being conducted?
This trial has 20 study locations across California, Colorado, Massachusetts, Texas, Milan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
RECRUITING · Phase 2
-
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
RECRUITING · Phase 2
-
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RECRUITING · Phase 2
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RECRUITING · Phase 2
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
ACTIVE NOT RECRUITING · Phase 2
-
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.